{
  "meta": {
    "data_length": 1,
    "message": "Document id doc:ema:ojemda retrieved successfully",
    "request_url": "http://api.moalmanac.org/documents?document_id=doc%3Aema%3Aojemda",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.013774,
    "timestamp_received": "2026-09-25T06:00:05.919638+00:00Z",
    "timestamp_returned": "2026-09-25T06:00:05.933412+00:00Z",
    "trace_id": "a8e29aee-1170-4d46-8841-4be31238598d"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "doc:ema:ojemda",
      "type": "Document",
      "documentType": "Regulatory approval",
      "name": "Ojemda (tovorafenib) [product information]. EMA.",
      "title": null,
      "aliases": [],
      "description": "Ipsen Pharma. Ojemda (tovorafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf. Revised May 2026. Accessed August 2, 2026.",
      "urls": [
        "https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf",
        "https://www.ema.europa.eu/en/medicines/human/EPAR/ojemda"
      ],
      "doi": null,
      "pmid": null,
      "extensions": [
        {
          "name": "agent",
          "value": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          },
          "description": "The organization that published this document."
        },
        {
          "name": "company",
          "value": "Ipsen Pharma",
          "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
        },
        {
          "name": "drug_name_brand",
          "value": "Ojemda",
          "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
        },
        {
          "name": "drug_name_generic",
          "value": "tovorafenib",
          "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
        },
        {
          "name": "first_publication_date",
          "value": "2026-05-11",
          "description": "The publication date for the initial version of this document."
        },
        {
          "name": "identification_number",
          "value": "EMEA/H/C/006140",
          "description": "Identification number used by the publishing organization."
        },
        {
          "name": "publication_date",
          "value": "2026-05-11",
          "description": "The publication date for the document."
        },
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this document is Active or Deprecated within moalmanac-db."
        }
      ]
    }
  ]
}